“Osteosarcoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Osteosarcoma Market.
The Osteosarcoma Pipeline report embraces in-depth commercial, regulatory, and Osteosarcoma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Osteosarcoma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Osteosarcoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Osteosarcoma treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Osteosarcoma therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Osteosarcoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Osteosarcoma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Osteosarcoma therapeutic market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Osteosarcoma Therapeutics Landscape
In general, the commonly available modalities for the treatment of osteosarcoma include chemotherapy, surgery, and radiation therapy. Although some novel insights have been offered for clinical and scientific relevance, minor progress has been made in osteosarcoma treatment following a significant survival improvement in the late 1980s with the addition of chemotherapy to surgery.
The mainstream chemotherapeutic agents for treatment include methotrexate, doxorubicin, cisplatin, and ifosfamide approved by the NCCN Guidelines. Since the introduction of chemotherapy, single-agent treatment of osteosarcoma has been considered inadequate, the majority of osteosarcoma treatment is based on a combination of two or more of only four drugs: doxorubicin, cisplatin, methotrexate, and ifosfamide. Therefore, treatment options available for first-line osteosarcoma patients consist of combinations including doxorubicin + cisplatin (DC), methotrexate + doxorubicin + cisplatin (MDC), and methotrexate + doxorubicin + cisplatin + ifosfamide (MDCI). The function of second-line chemotherapy for recurrent OS is much less well-defined and there is no accepted standard regimen.
There are approx. 30+ key Osteosarcoma companies developing therapies for Osteosarcoma. Currently, Lee Pharmaceutical is leading the therapeutics market with its Osteosarcoma drug candidates in the most advanced stage of clinical development.
Osteosarcoma Companies Actively Working in the Therapeutic Market Include:
-
AlaMab Therapeutics
-
Zentalis Pharmaceuticals
-
Merck Eprova
-
Eisai Co Ltd
-
George Clinical Pty Ltd
-
Y-mAbs Therapeutics
-
Jiangsu Hengrui Medicine
-
AstraZeneca
-
Advenchen Laboratories LLC
-
Innovent Biologics
-
PersonGen BioTherapeutics (Suzhou)
-
Cellectar Biosciences, Inc.
-
Merck & Co
-
Hutchison Medipharma Limited
-
MacroGenics
-
Gradalis, Inc.
-
Shanghai Pharmaceuticals Holding
-
Celgene
-
Oncternal Therapeutics
-
Valent Technologies
And Many Others
Emerging and Marketed Osteosarcoma Drugs Covered in the Report Include:
-
KAB001: Lee’s Pharmaceutical Limited
-
Lenvatinib: Eisai Co Ltd/Merck & Co
-
Camrelizumab: Jiangsu Hengrui Medicine
-
ZN c3: Zentalis Pharmaceuticals
-
ALMB 0168: AlaMab Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Osteosarcoma Companies Working in the Market @
https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight
Analysis of Emerging Osteosarcoma Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Osteosarcoma products have been categorized under various ROAs such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Molecule Type
Osteosarcoma products have been categorized under various Molecule types such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Learn How the Osteosarcoma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Osteosarcoma Treatment Patterns
4. Osteosarcoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Osteosarcoma Late Stage Products (Phase-III)
7. Osteosarcoma Mid-Stage Products (Phase-II)
8. Osteosarcoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteosarcoma Discontinued Products
13. Osteosarcoma Product Profiles
14. Major Osteosarcoma Companies in the Market
15. Key Products in the Osteosarcoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Osteosarcoma Unmet Needs
18. Osteosarcoma Future Perspectives
19. Osteosarcoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Elevate your business strategy and make informed decisions in a rapidly evolving healthcare landscape, guided by our comprehensive research offerings @ Healthcare Market Research
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices